INJECTAFER
LOE Approachingferric carboxymaltose injection
NDAINTRAVENOUSSOLUTION
Approved
Jul 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
4/8 — Partial
INJECTAFER (ferric carboxymaltose injection) is (iii) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron. First approved in 2013.
Drug data last refreshed 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INJECTAFER is a ferric carboxymaltose intravenous injection approved in 2013 for treating iron deficiency anemia. The drug delivers ferric iron complexed with carboxymaltose, a carbohydrate polymer that controls iron release and bioavailability. It addresses anemia across multiple patient populations requiring rapid iron repletion.
LOE Approaching1.8 years to LOE
With loss of exclusivity approaching in February 2028 (1.8 years remaining), the brand team faces declining market share and budget reallocation; team consolidation and transition planning are likely underway.
Mechanism of Action
(III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.